ran a clinical trials unit with an interest in rosacea until 2014 (specific). C.E.D.W. has been an invited speaker for AbbVie, Galderma and Janssen (specific); and has accepted invitations to attend congresses and meetings related to psoriasis/biologics (nonspecific). T.A.L. has been on advisory boards for Galderma, La Roche-Posay and Novartis (specific); and has been an invited speaker for Novartis (specific). D.S. received travel and conference sponsorship for the 2018 European Academy of Dermatology and Venereology spring conference from Galderma (specific). This is a guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, which includes the Therapy & Guidelines Subcommittee. Members of the Clinical Standards Unit that have been involved are: N.

Potential therapies used in MIS-A include intravenous immunoglobulin (IVIg), aspirin, anticoagulation, corticosteroids and tocilizumab. 1 With our evolving understanding of K-MIS-A, treatment protocols are yet to be standardized. Although we gave only anticoagulants to our patient, he recovered completely without any cardiac sequelae, as seen at follow-up. The CDC's detailed data on 27 cases of MIS-A included two cases with deranged inflammatory markers, ECG and TTE changes, which recovered on only anticoagulants without IVIg or steroids. 1 Hence, there might be a subset of patients with K-MIS-A who may recover spontaneously without conventional therapies. The focus of our case is to reiterate the possibility of COVID-19-associated K-MIS-A and timely diagnosis through early identification of dermatological manifestations and antibody testing, even when COVID-19 RT-PCR is negative. Further information on the investigations is available on direct request.

No abstract